Clinical Trial

Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke

Study acronym: ARCHIMEDES
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-29; most recent amendment 2026-02-10.
Trial Details
NCT Number NCT06396858
Lead Sponsor Brazilian Clinical Research Institute
Collaborators: Alliança Diagnostic
Conditions Ischemic Stroke
Enrollment 4,500 participants
Start Date 2026-07
Primary Completion 2027-08 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-11